Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has announced the acceptance of a new indication application for the combination of Benmelstobart Injection and Anlotinib Hydrochloride Capsule, aimed at treating advanced renal cell carcinoma (RCC). This marks the third indication for Benmelstobart and the eighth for Anlotinib, with Phase III trials showing significant patient benefits over Sunitinib. The company continues to focus on innovative R&D to advance its pipeline of products.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
